Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...

Lung cancer is a big problem. It claims many lives each year. Around 160,000 people die annually in the US. This figure is ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman.

Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a ...

Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of ...

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

Global Non Small-Cell Lung Cancer Market, by Type The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031.

Vaping might be safer than cigarette smoking, but they carry their own health risks. A New Jersey man’s electronic cigarette ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...